Skip to main content

RT @RichardPAConway: Mease et al. TYK2i Deucravacitinib in PsA. Phase 2 RCT 52 week results. PASDAS, DAPSA efficacy main

Nov 14, 2022 6:21 am
Social Author Name
Richard Conway
Tweet Content
Mease et al. TYK2i Deucravacitinib in PsA. Phase 2 RCT 52 week results. PASDAS, DAPSA efficacy maintained through week 52. No new safety concerns. @RheumNow #ACR22 Abstr#1598 https://t.co/sRKkgkYtQJ https://t.co/YMXMEH3wsq
Show on Archive Page
On
Display in Search Results
On
PDQ
Off
×